Withaferin A is a potent inhibitor of angiogenesis

Angiogenesis

Volumn 7, Issue 2, 2004, Pages 115-122

  Mohan, Royce ^a   Hammers, Hans ^a   Bargagna Mohan, Paola ^b   Zhan, Xiaoguo ^a   Herbstritt, Christopher ^a   Ruiz, Antonio ^a   Zhang, Li ^a   Hanson, Art ^a   Conner, Barry ^a   Rougas, John ^a   Pribluda, Victor ^a  

^a ENTREMED INC   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

angiogenesis inhibitor; endothelial cell; natural product; NF kappa B; withaferin A

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 1; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; UBIQUITIN; WITHAFERIN A; WITHANIA SOMNIFERA EXTRACT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; WITHANIA SOMNIFERA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ERGOSTEROL; HUMANS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PLANTS, MEDICINAL; PROTEASOME ENDOPEPTIDASE COMPLEX; SPHEROIDS, CELLULAR; UBIQUITIN; UMBILICAL VEINS;

ANIMALIA; WITHANIA; WITHANIA SOMNIFERA;

EID: 20844449388     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-1026-3     Document Type: Article

References (40)

1. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible or angiogenesis. J Exp Med 1971; 133: 275-88.
2. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann Rheum Dis 1992; 517: 919-25.
3. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J 1992; 6: 886-92.
4. Battegay EJ. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73: 333-46.
5. Oliver SJ, Brahn E. Combination therapy in rheumatoid arthritis: The animal model perspective. J Rheumatol 1996; 44 (Suppl): 56-60.
6. Misra R. Modern drug development from traditional medicinal plants using radioligand receptor-binding assays. Med Res Rev 1998; 18: 383-402.
7. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): Altern Med Rev 2000; 5: 334-46.
8. Upton R. Ashwagandha Root. Santa Cruz, California: American Herbal Pharmacopoeia 2000.
9. Kulkarni RR, Patki PS, Jog VP et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991; 33: 91-5.
10. Shohat B, Gitter S, Abraham A, Lavie D. Antitumor activity of withaferin A. Cancer Chemoth Rep 1967; 51: 271-6.
11. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998; 143: 1341-52.
12. Burbridge MF, West DC. Rat Aortic Ring 3D Model of Angiogenesis in Vitro. In Clifford Murray J (ed): Methods in Molecular Medicine: Angiogenesis Protocols. Totowa, New Jersey: Humana Press 2001; 185.
13. Mohan R, Sivak J, Ashton P et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275: 10405-12.
14. La Vallee TM, Zhan X, Herbstritt CJ et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002; 62: 3691-7.
15. Kiener PA, Marek F, Rodgers G et al. Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol 1988; 141: 870-4.
16. Passanti A, Taylor RM, Pili R et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-28.
17. Klein S, de Fougerolles AR, Blaikie P et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002; 16: 5912-22.
18. Shono T, Ono M, Izumi H et al. Involvement of the transcription factor NF-kappa B in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996; 8: 4231-9.
19. Kupchan SM, Anderson WK, Bollinger P et al. Tumor inhibitors. XXXIX. Active principles of Acnistus arborescens. Isolation and structural and spectral studies of withaferin A and withacnistin. J Org Chem 1969; 34: 3858-66.
20. Pelletier SW, Mody NV, Nowacki J, Bhattacharyya J. Carbon-13 Nuclear magnetic resonance spectral analysis of naturally occurring withanolides and their derivatives. J Nat Prod 1979; 42: 512-21.
21. Glotter E. Withanolides and related ergostane-type steroids. Nat Prod Rep 1991; 8: 415-40.
22. Pollet I, Opina CJ, Zimmerman C et al. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood 2003; 102: 1740-2.
23. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-85.
24. Fuegner A. Inhibition of immunologically induced inflammation by the plant steroid withaferin A. Arzneimittel Forsch 1973; 23: 932-5.
25. Shohat B, Kirson I, Lavie D. Immunosuppressive activity of two plant steroidal lactones, withaferin A and withanolide E. Biomedicine 1978; 28: 18-24.
26. Furmanowa M, Gajdzis-Kuls D, Ruszkowska J et al. In vitro propagation of Withania somnifera and isolation of withanolides with immunosuppressive activity. Planta Med 2001; 67: 146-9.
27. Sharada AC, Solomon FE, Devi PU et al. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol 1996; 35: 95-100.
28. Brach MA, Henschler R, Mertelsmann RH, Herrmann F. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991; 88: 691-5.
29. Devi PU, Akagi K, Ostapenko V et al. Withaferin A: A new radiosensitizer from the Indian medicinal plant Withania somnifera. Int J Radiat Biol 1996; 69: 193-7.
30. Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NF-kappa B in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-6.
31. Kwok BH, Koh B, Ndubuisi MI et al. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001; 8: 759-66.
32. Oikawa T, Sasaki T, Nakamura M et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-8.
33. Mezquita J, Mezquita B, Pau M, Mezquita C. Down-regulation of Fit-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem 2003; 89: 1138-47.
34. Kumeda SI, Deguchi A, Toi M et al. Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 1999; 19: 3961-8.
35. Willems AR, Lanker S, Patton EE et al. Cdc53 targets phosphorylated Gl cyclins for degradation by the ubiquitin proteolytic pathway. Cell 1996; 86: 453-63.
36. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21: 245-73.
37. Sabichi AL, Demierre M-F, Hawk ET et al. Frontiers in Cancer Prevention Research. Cancer Res 2003; 63: 5649-55.
38. Tosetti F, Ferrari N, De Flora S, Albini A. 'Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
39. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 10: 768-80.
40. Jayaprakasam B, Nair MG. Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron 2003; 59: 841-9.